Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery.
As the pharmaceuticals industry turns its attention to precision medicine — the search for ever more tailored treatments for specific diseases using genetic engineering — Octant is using the same technologies to engage in drug discovery and diagnostics on a mass scale.
The company’s technology genetically engineers DNA to act as an identifier for the most common drug receptors inside the human genome. Basically, it’s creating QR codes that can flag and identify how different protein receptors in cells respond to chemicals. These are the biological sensors which help control everything from immune responses to the senses of sight and smell, the firing of neurons; even the release of hormones and communications between cells in the body are regulated.
“Our discovery platform was designed to map and measure the interconnected relationships between chemicals, multiple drug receptor pathways and diseases, enabling us to engineer multi-targeted drugs in a more rational way, across a wide spectrum of targets,” said Sri Kosuri, Octant’s co-founder and chief executive officer, in a statement.
Octant’s work is based on a technology first developed at the University of California Los Angeles by Kosuri and a team of researchers, which slashed the cost of making genetic sequences to $2 per gene from $50 to $100 per gene.
“Our method gives any lab that wants the power to build its own DNA sequences,” Kosuri said in a 2018 statement. “This is the first time that, without a million dollars, an average lab can make 10,000 genes from scratch.”
Joining Kosuri in launching Octant is Ramsey Homsany, a longtime friend of Kosuri’s, and a former executive at Google and Dropbox. Homsany happened to have a background in molecular biology from school, and when Kosuri would talk about the implications of the technology he developed, the two men knew they needed to for a company.
“We use these new tools to know which bar code is going with which construct or genetic variant or pathway that we’re working with [and] all of that fits into a single well,” said Kosuri. “What you can do on top of that is small molecule screening… we can do that with thousands of different wells at a time. So we can build these maps between chemicals and targets and pathways that are essential to drug development.”
Before coming to UCLA, Kosuri had a long history with companies developing products based on synthetic biology on both the coasts. Through some initial work that he’d done in the early days of the biofuel boom in 2007, Kosuri was connected with Flagship Ventures, and the imminent Harvard-based synthetic biologist George Church. He also served as a scientific advisor to Gen9, a company acquired by the multi-billion dollar synthetic biology powerhouse, Ginkgo Bioworks.
“Some of the most valuable drugs in history work on complex sets of drug targets, which is why Octant’s focus on polypharmacology is so compelling,” said Jason Kelly, the co-founder and CEO of Gingko Bioworks, and a member of the Octant board, in a statement. “Octant is engineering a lot of luck and cost out of the drug discovery equation with its novel platform and unique big data biology insights, which will drive the company’s internal development programs as well as potential partnerships.”
The new technology arrives at a unique moment in the industry where pharmaceutical companies are moving to target treatments for diseases that are tied to specific mutations, rather than look at treatments for more common disease problems, said Homsany.
“People are dropping common disease problems,” he said. “The biggest players are dropping these cases and it seems like that just didn’t make sense to us. So we thought about how would a company take these new technologies and apply them in a way that could solve some of this.”
One reason for the industry’s turn away from the big diseases that affect large swaths of the population is that new therapies are emerging to treat these conditions which don’t rely on drugs. While they wouldn’t get into specifics, Octant co-founders are pursuing treatments for what Kosuri said were conditions “in the metabolic space” and in the “neuropsychiatric space”.
Helping them pursue those targets, since Octant is very much a drug development company, is $30 million in financing from investors led by Andreessen Horowitz.
“Drug discovery remains a process of trial and error. Using its deep expertise in synthetic biology, the Octant team has engineered human cells that provide real-time, precise and complete readouts of the complex interactions and effects that drug molecules have within living cells,” said Jorge Conde, general partner at Andreessen Horowitz, and member of the Octant board of directors. “By querying biology at this unprecedented scale, Octant has the potential to systematically create exhaustive maps of drug targets and corresponding, novel treatments for our most intractable diseases.”